3Morrison DH, Rahardja D, King E, et al. Tumor biomarker expression relative to age and molecular subtypes of invasive breast canoe [J]. Br J Cancer, 2012, 107(2): 382-387.
4Obiorah I, Jordan V C. Progress in endocrine approaches to the treatment and prevention of breast cancer [J]. Maturitas, 2011, 70(4): 315-321.
5Wong AL, Lee SC. Mechanisms of resistance to Trastuzumab and novel therapeutic strategies in Her2-positive breast cancer [J]. Int J Breast Cancer, 2012, Article 10415170, 13 pages.
6de Ruijter TC, Veeck J, de Hoon JP, et al. Characteristics of triple-negative breast cancer [J]. J Cancer Res Clin Oncol, 2011, 137(2) : 183-192.
7Palucka K, Ueno H, Fay J, et al. Dendritic cells and immunity against cancer [J]. J Intern Med, 2011, 269(1) : 64-73.
8Jahnisch H, Fussel S, Kiessling A, et al. Dendritic cell-based immunotherapy for prostate cancer [J/OL J. Clin Dev Immunol, 2010, doi , 10.1155/2010/517493.
9J Franks HA , Wang Q, Patel PM. New anticancer immunotherapies [J]. Anticancer Res, 2012, 32(7): 2439-2453.
10Yamanaka R, Kajiwara K. Dendritic cell vaccines [J]. Adv Exp Med Bioi, 2012, 746(4): 187-200.
